Fluidigm Introduces High-Parameter Maxpar Mass Cytometry Panels for Immuno-Oncology Research
Fluidigm Corporation (NASDAQ:FLDM) announced the introduction of a modular set of high-parameter Maxpar® mass cytometry panels for immuno-oncology research. Designed for use with Helios™ and CyTOF® systems, the Immuno-Oncology Maxpar [more...]